Market Access And Reimbursement In Canada – Changes At CADTH Pharma Market Access Insights

Inhoud geleverd door Mtech Access - Powered by Petauri. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Mtech Access - Powered by Petauri of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Pharma Market Access Insights - from Mtech Access »
Market access and reimbursement in Canada – changes at CADTH

12d ago 47:43

MP3•Thuis aflevering

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).
We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:

The market access landscape in Canada
Upcoming changes at CADTH
What Canadian payers expect from your value proposition
Opportunities and challenges when launching new medicines/medical devices/diagnostics in Canada
How Canada compares to the USA/key European launch markets
What this means for your global market access strategy

This episode was first broadcast as a live webinar in March 2024. Learn more at https://mtechaccess.co.uk/market-access-canada-changes-cadth/
Learn more about the Canadian healthcare market and launching new pharma and medtech innovations at: https://mtechaccess.co.uk/launching-healthcare-products-in-canada/

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Hoofdstukken

1. Welcome and introductions (00:00:00)

2. Challenges of achieving access for a pharma or medtech product in Canada (00:02:17)

3. The role of CADTH in HTA recommendations in Canada (00:04:18)

4. The time-limited drug reimbursement recommendation (00:05:58)

5. How pharmaceutical pricing works in Canada overall (00:10:38)

6. Introduction of the Canadian Drug Agency (CDA) (00:14:16)

7. Impact of European Joint Clinical Assessment (JCA) in Canada (00:24:28)

8. CDA and the regulatory landscape in Canada (00:26:55)

9. CADTH for Medtech (00:30:08)

10. Rare disease strategy in Canada (00:35:42)

11. Schemes for registry data and real-world evidence (00:39:22)

12. Key lessons and final thoughts (00:43:10)

59 afleveringen

#Science #Fitness #Biology #Business #Medicine #Mtech Access #Pharmaceutical #Pharma #Market Access #Health Economics #Heores #Medtech #NHS #Healthcare